Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,363 | 253 | 1,090 |
| Samples | 703 | 160 | 526 |
| Peptides | 601 | 113 | 492 |
Function
DDX60L · DExD/H-box 60 like
This gene encodes a member of the DExD/H-box helicase family of proteins, a subset of the super family 2 helicases. Members of the DExD/H-box helicase family share a conserved functional core comprised of two RecA-like globular domains. These domains contain conserved motifs that mediate ATP binding, ATP hydrolysis, nucleic acid binding, and RNA unwinding. In addition to functions in RNA metabolism, members of this family are involved in anti-viral immunity and act as cytosolic sensors of viral nucleic acids. The protein encoded by this gene has been shown to inhibit hepatitis C virus replication in response to interferon stimulation in cell culture. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2016].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 551 amino-acid changes on canonical ENST00000511577 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in DDX60L · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in DDX60L – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 5/40 12% | 0/0 0% |
| Melanoma | 17/210 8% | 113/1899 6% |
| Oral Cavity Carcinoma | 3/54 6% | 0/0 0% |
| Endometrial Carcinoma | 8/42 19% | 28/612 5% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 6/133 5% |
| Hodgkins Lymphoma | 3/16 19% | 3/122 2% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 24/304 8% | 40/1390 3% |
| Squamous Cell Lung Carcinoma | 7/57 12% | 22/810 3% |
| Acute Myeloid Leukemia | 3/90 3% | 0/0 0% |
| Plasma Cell Myeloma | 8/44 18% | 1/305 0% |
| Bladder Carcinoma | 4/58 7% | 22/956 2% |
| Colorectal Carcinoma | 18/143 13% | 60/3239 2% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Small Cell Lung Carcinoma | 2/9 22% | 13/752 2% |
| Neuroendocrine Tumour | 8/154 5% | 6/577 1% |
| Other Solid Cancers | 2/94 2% | 26/1515 2% |
| Germ Cell Tumour | 2/25 8% | 1/169 1% |
| Thyroid Gland Carcinoma | 1/45 2% | 24/1592 2% |
| Gastric Carcinoma | 5/74 7% | 23/1809 1% |
| Ewings Sarcoma | 1/63 2% | 3/262 1% |
| Biliary Tract Carcinoma | 2/54 4% | 10/950 1% |
| Cervical Carcinoma | 2/35 6% | 3/422 1% |
| Esophageal Carcinoma | 0/23 0% | 8/769 1% |
| Rhabdomyosarcoma | 2/33 6% | 0/171 0% |
| Head and Neck Carcinoma | 1/85 1% | 14/1574 1% |
| Hepatocellular Carcinoma | 0/46 0% | 20/2210 1% |
| Burkitts Lymphoma | 2/32 6% | 0/196 0% |
| Ovarian Carcinoma | 3/109 3% | 6/998 1% |
| Non-Cancerous | 2/104 2% | 5/830 1% |
Mutation Distribution
Where DDX60L is mutated · all tissues, split by cell line vs tissue
How many mutations in DDX60L were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,363 mutations in DDX60L
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|